



Atty. Dkt. No. 065678-0108

1FW
K
CC

Applicant: Naoshi Fukushima, et al.

Title: AGONIST ANTIBODIES

Appl. No.: 10/645,085

Filing Date: 10/7/2002

Examiner: Bristol, Lynn Anne

Art Unit: 1643

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

03/30/2006 JADD01 00000010 10645085

01 FC:1806

180.00 0P

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

An English abstract of the foreign-language document is provided. The absence of a full translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.


FEE

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.


Respectfully submitted,

Date 3/28/06

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

for Stephen B. Maebius *Matthew Mulkeen*
Attorney for Applicant *Reg. No. 44,250*
Registration No. 35,264



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
Date Submitted: March 29, 2006			
(use as many sheets as necessary)			
Sheet	1	of	5
Application Number		10/645,085	
Filing Date		01/24/2003	
First Named Inventor		Naoshi Fukushima	
Group Art Unit		1643	
Examiner Name		Bristol, Lynn	
Attorney Docket Number		065678-0108	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	C1	5,837,242		Holliger et al.	11-17-1998	
	C2	5,840,344		Fukushima	11-24-1998	
	C3	5,885,574		Elliott	03-23-1999	
	C4	6,719,972	B1	Gribben et al.	04-13-2004	
	C5	6,759,043	B2	Fukushima	07-06-2004	
	C6	6,579,692	B1	Fukushima	06-17-2003	
	C7	2003/0157100	A1	Fukushima et al.	08-2003	
	C8	2003/0211108	A1	Fukushima et al.	11-2003	
	C9	2003/0147894	A1	FUKUSHIMA et al.	08/07/2003	
	C10	2003/0157577	A1	Fukushima et al.	08-2003	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	C11	WO	91/16928		Cell-Tech Limited	11-14-1991		
	C12	WO	96/36360	A	UNIV MINNESOTA	11-21-1996		
	C13	WO	99/03495	A	BETH ISRAEL HOSPITAL	01-28-1999		
	C14	WO	99/10494		Genentech, Inc.	03-04-1999		
	C15	JP	11-092500		Chugai Pharma. Co. Ltd.	04-06-1999		A
	C16	WO	99/17364		Raytheon Company	04-08-1999		
	C17	EP	1 035 132		Chugai Seiyaku Kabushiki Kaisha	09-13-2000		
	C18	WO	02/078612	A	PURDUE PHARMA LP	10-10-2002		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C19	BARTLEY, T., et al., "Identification and Cloning of a Megakaryocyte Growth and Development Factor That is a Ligand for the Cytokine Receptor Mpl," Cell, Vol. 77, pp. 1117-1124 (1994).	
	C20	BAZIL, V., et al., "Apoptosis of Human Hematopoietic Progenitor Cells Induced by Crosslinking of Surface CD43, the Major Sialoglycoprotein of Leukocytes," pp. 502-511 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/645,085
				Filing Date	01/24/2003
				First Named Inventor	Naoshi Fukushima
				Group Art Unit	1643
				Examiner Name	Bristol, Lynn
Date Submitted: March 29, 2006				Attorney Docket Number	065678-0108
(use as many sheets as necessary)					
Sheet	2	of	5		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	C21	BERGER, S. L., et al., "Inhibition of Intractable Nucleases with Ribonucleoside-Vanadyl Complexes: Isolation of Messenger Ribonucleic Acid From Resting Lymphocytes", <i>Biochemistry</i> , Vol. 18, No. 23, pp. 5143-5149 (1979)		
	C22	BURTHEM, et al., "Hairy Cell Interactions with Extracellular Matrix: Expression of Specific Integrin Receptors and Their Role in the Cell's Response to Specific Adhesive Proteins," <i>Blood</i> , Vol. 84, No. 3, pp. 873-882 (1994).		
	C23	CALDAS, C., et al., <i>Mol. Immunol.</i> , Vol. 39, No. 15, pp. 941-952 (2003).		
	C24	CHIEN, N. C., et al., <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 84, No. 14, pp. 5532-5536 (1989).		
	C25	CHIRGWIN, J. M., et al., "Isolation of Biologically Active Ribonucleic Acid from Sources Enriched in Ribonuclease", <i>Biochemistry</i> , Vol. 18, No. 24, pp. 5294-5299 (1979).		
	C26	COOPER, D., et al., "Transendothelial migration of neutrophils involves integrin-associated protein (CD47)," <i>Proc. Natl. Acad. Sci. USA</i> , pp. 3978-3982 (1995).		
	C27	de SAUVAGE, F., et al., "Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the c-Mpl Ligand," <i>Nature</i> , Vol. 369, pp. 533-538 (1994).		
	C28	de ST. GROTH, S. F., et al., "Production of Monoclonal Antibodies: Strategy and Tactics," <i>Journal of Immunological Methods</i> , Vol. 35, pp. 1-21 (1980)		
	C29	DENG, B., et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," <i>Blood</i> , Vol. 92, No. 6, pp. 1981-1988 (1991).		
	C30	FELGENHAUER, M., et al., "Nucleotide Sequences of the cDNAs Encoding the V-Regions of H- and L-Chains of a Human Monoclonal Antibody Specific to HIV-1 - gp41," <i>Nucleic Acids Research</i> , Vol. 18, No. 16, p. 4927 (1990).		
	C31	FUJIMOTO, T., et al., <i>Blood</i> , Vol. 86, No. 6, pp. 2174-2182 (1995).		
	C32	FUKUSHIMA, N., et al., "Enhanced Hematopoiesis In Vivo and In Vitro by Splenic Stromal Cells Derived From the Mouse With Recombinant Granulocyte Colony-Stimulating Factor", <i>Blood</i> , Vol. 80, No. 8, pp. 1914-1922 (1992)		
	C33	GALFRE, G., et al., "Preparation of Monoclonal Antibodies: Strategies and Procedures," <i>Methods in Enzymology</i> , Vol. 73, pp. 3-46 (1981)		
	C34	GALFRE, G., et al., "Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG," <i>Nature</i> , Vol. 277, pp. 131-133 (1979)		
	C35	GENESTIER, L., et al., "Antibodies to HLA Class I α 1 Domain Trigger Apoptosis of CD 40-Activated Human B Lymphocytes," <i>Blood</i> , Vol. 90, No. 2, pp. 726-735 (1997)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/645,085
				Filing Date	01/24/2003
				First Named Inventor	Naoshi Fukushima
				Group Art Unit	1643
				Examiner Name	Bristol, Lynn
Date Submitted: March 29, 2006				Attorney Docket Number	065678-0108
(use as many sheets as necessary)					
Sheet	3	of	5		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C36	GIUSTI, A. M., et al., Proc. Natl. Acad. Sci. USA, Vol. 84, No. 9, pp. 2926-2930 (1987).	
	C37	GODING, Monoclonal Antibodies: Principles and Practice, Academic Press, second Ed, pp. 125-129 (1986)	
	C38	GRELL, M., et al., "TR50 and TR80 Tumor Necrosis Factor (TNF)-Receptors Can Independently Mediate Cytolysis", Lymphokine and Cytokine Research, vol. 12, no. 3, pp. 143-148 (June 1993).	
	C39	GUSSOW, D., et al., Methods in Enzymology, Vol. 203, pp. 99-121 (1991).	
	C40	HOPP, T., et al., "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," Bio/Technology, Vol. 6, pp. 1204-1210 (1988).	
	C41	HUDSON, P. J., et al., "High avidity scFv multimers; diabodies and triabodies" J. Immunol. Methods, Elsevier Science Publishers, Vol. 231, No. 1-2, pp. 177-189 (1999).	
	C42	HUSTON, J., et al., "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in <i>Escherichia Coli</i> ," Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 5879-5883 (1988).	
	C43	ITOH, N., et al., "The Polypeptide Encoded by the cDNA for Human Cell Surface Antigen Fas Can Mediate Apoptosis," Cell, Vol. 66, pp. 233-243 (1991)	
	C44	JIANG et al., "A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2," J. Biol. Chem., February 11, 2005, Vol. 280, No. 6, pp. 4656-4662.	
	C45	KEARNEY, J. F., et al., "A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression But Permits The Construction of Antibody-Secreting Hybrid Cells Lines," The Journal of Immunology, Vol. 123, No. 4, pp. 1548-1550 (1979)	
	C46	KIPRIYANOV, S., et al., "Bispecific CD3 X CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells," Int. J. Cancer, Vol. 77, pp. 763-772 (1988).	
	C47	KOHLER, G., et al., "Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion," Eur. J. Immunol., Vol. 6, pp. 511-519 (1976)	
	C48	LARRICK, J. W., et al., "Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes From Single Hybridoma Cells", Bio/Technology, Vol. 7, pp. 934-938 (1989)	
	C49	LAW, L. W., et al., "Observations On The Effect Of A Folic-Acid Anatagonist On Transplantable Lymphoid Leukemias In Mice", Journal of the National Cancer Institute, Vol. 10, pp. 179-193 (1949).	
	C50	LEI, S. et al., "Characterization of the <i>Erwinia Carotovora pelB</i> Gene and Its Product Pectate Lyase," J. Bacteriol., pp. 4379-4383 (1987).	
	C51	LINDBERG, et al., "Rh-Related Antigen CD47 is the Signal-Transducer Integrin-Associated Protein," J. Biol. Chem., Vol. 269, pp. 1567-1570 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2006 (use as many sheets as necessary)				Application Number	10/645,085
				Filing Date	01/24/2003
				First Named Inventor	Naoshi Fukushima
				Group Art Unit	1643
				Examiner Name	Bristol, Lynn
Sheet	4	of	5	Attorney Docket Number	065678-0108

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C52	MARGULIES, D. H., et al., "Somatic Cell Hybridization of Mouse Myeloma Cells," Cell, Vol. 8, pp. 405-415 (1976)	
	C53	MARIUZZA, R. A., et al., Annu. Rev. Biophys. Biophys. Chem., Vol. 16, pp. 139-159 (1987)	
	C54	MAWBY, W. J., et al., "Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumor marker OA3," Biochem. J., Vol. 304, pp. 525-530 (1994)	
	C55	METHIA, N., et al., "Oligodeoxynucleotides Antisense to the Proto-Oncogene <i>c-Mpl</i> Specifically Inhibit In Vitro Megakaryocytopoiesis," Blood, Vol. 82, No. 5, pp. 1395-1401 (1993).	
	C56	MILILI, M., et al., "The VDJ Repertoire Expressed in Human preB Cells Reflects the Selection of <i>Bona Fide</i> Heavy Chains," Eur. J. Immunol., Vol. 26, pp. 63-69 (1996).	
	C57	NAKAYAMA, et al., J. Mole. Med., Vol. 83, PP. 316-320 (2005).	
	C58	PAUL, Fundamental Immunology, Raven Press, NY, Chapter 8, p. 242 (1993)	
	C59	PETTERSON, "CD47 and death signaling in the immune system," Apoptosis Vol. 5, pp. 299-306 (2000)	
	C60	REINHOLD et al., "In vivo expression of alternatively spliced forms of integrin-associated protein (CD47)," J. Cell Science, 1995, vol. 108, pp. 3419-3425.	
	C61	RIECHMANN, L., et al., "Reshaping Human Antibodies for Therapy", Nature, Vol. 332, pp. 323-327 (1988).	
	C62	ROUE, G., et al., Biochimie, Vol. 85, pp. 741-746 (2003).	
	C63	RUDIHOFF, et al., Proc. Natl. Acad. Sci. USA Vol. 79, p. 1979 (1982)	
	C64	SCHICKEL, et al., "Gene for Integrin-Associated Protein (IAP, CD47): Physical Mapping, Genomic Structure, and Expression Studies in Skeletal Muscle," Biochem. Cell. Biol., Vol. 80, No. 2, pp. 169-176 (2002).	
	C65	SCHWARTZ, M. A., et al., "A 50-kDa Integrin-associated Protein Is Required for Integrin-regulated Calcium Entry in endothelial Cells," J. Biol. Chem., Vol. 268, No. 27, pp. 19931-19934 (1993)	
	C66	SHIGETA, M., et al., "Sperm-immobilizing monoclonal antibody to human seminal plasma antigens," Clin. Exp. Immunol., Vol. 42, pp. 458-462 (1980)	
	C67	SHULMAN, M., et al., "A better cell line for making hybridomas secreting specific antibodies," Nature, Vol. 276, pp. 269-270 (1978)	
	C68	SKOLNICK, et al., "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," Trends in Biotechnology, Vol. 18, pp. 34-39 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 29, 2006 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/645,085
				Filing Date	01/24/2003
				First Named Inventor	Naoshi Fukushima
				Group Art Unit	1643
				Examiner Name	Bristol, Lynn
				Attorney Docket Number	065678-0108
Sheet	5	of	5		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
	C69	SOUYRI, M., et al., "A Putative Truncated Cytokine Receptor Gene Transduced by the Myeloproliferative Leukemia Virus Immortalizes Hematopoietic Progenitors," Cell, Vol. 63, December 21, pp. 1137-1147 (1990).		
	C70	SPAARGAREN, M., et al., "Antibody-induced Dimerization Activates the Epidermal Growth Factor Receptor Tyrosine Kinase", The J. Biol. Chem., Vol. 266, No. 3, pp. 1733-1739 (1981).		
	C71	STANCOVSKI et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth," Proc. Natl. Acad. Sci. USA, October 1991, Vol. 88, pp. 8691-8695.		
	C72	TROWBRIDGE, I. S., "Interspecies Spleen-Myeloma Hybrid Producing Monoclonal Antibodies Against Mouse Lymphocyte Surface Glycoprotein, T200," J. Exp. Med., Vol. 148, pp. 313-323 (1978)		
	C73	XIE, et al, "Direct demonstration of MuSK involvement in acetylcholine receptor clustering through identification of agonist ScFv," Nature Biotechnology, Vol. 15, pp. 768-771 (1997).		
	C74	YELTON, D. E., et al., "Fusion of Mouse Myeloma and Spleen Cells," Current Topics in Microbiology and Immunology, Vol. 81, pp. 1-7 (1978)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.